nodes	percent_of_prediction	percent_of_DWPC	metapath
Frovatriptan—Pain in jaw—Capecitabine—esophageal cancer	0.0223	0.0267	CcSEcCtD
Frovatriptan—Vasospasm—Capecitabine—esophageal cancer	0.0213	0.0255	CcSEcCtD
Frovatriptan—Dysaesthesia—Capecitabine—esophageal cancer	0.0168	0.0201	CcSEcCtD
Frovatriptan—Chest tightness—Capecitabine—esophageal cancer	0.0155	0.0185	CcSEcCtD
Frovatriptan—Disorder sight—Capecitabine—esophageal cancer	0.0153	0.0183	CcSEcCtD
Frovatriptan—Pain—Carboplatin—esophageal cancer	0.0103	0.0123	CcSEcCtD
Frovatriptan—Laryngitis—Capecitabine—esophageal cancer	0.0101	0.0121	CcSEcCtD
Frovatriptan—Hiccups—Cisplatin—esophageal cancer	0.00987	0.0118	CcSEcCtD
Frovatriptan—Ventricular fibrillation—Capecitabine—esophageal cancer	0.0095	0.0114	CcSEcCtD
Frovatriptan—Body temperature increased—Carboplatin—esophageal cancer	0.00949	0.0113	CcSEcCtD
Frovatriptan—Coagulopathy—Capecitabine—esophageal cancer	0.00935	0.0112	CcSEcCtD
Frovatriptan—Hyperaesthesia—Capecitabine—esophageal cancer	0.00927	0.0111	CcSEcCtD
Frovatriptan—Myocardial ischaemia—Capecitabine—esophageal cancer	0.00905	0.0108	CcSEcCtD
Frovatriptan—Tingling sensation—Capecitabine—esophageal cancer	0.00905	0.0108	CcSEcCtD
Frovatriptan—Rigors—Capecitabine—esophageal cancer	0.00891	0.0107	CcSEcCtD
Frovatriptan—Chest discomfort—Capecitabine—esophageal cancer	0.00823	0.00983	CcSEcCtD
Frovatriptan—Polyuria—Cisplatin—esophageal cancer	0.00816	0.00975	CcSEcCtD
Frovatriptan—Gastrooesophageal reflux disease—Capecitabine—esophageal cancer	0.00806	0.00963	CcSEcCtD
Frovatriptan—Hypocalcaemia—Capecitabine—esophageal cancer	0.00795	0.0095	CcSEcCtD
Frovatriptan—Nocturia—Capecitabine—esophageal cancer	0.00785	0.00937	CcSEcCtD
Frovatriptan—Amnesia—Cisplatin—esophageal cancer	0.00763	0.00911	CcSEcCtD
Frovatriptan—Bone pain—Capecitabine—esophageal cancer	0.0076	0.00908	CcSEcCtD
Frovatriptan—Gait disturbance—Capecitabine—esophageal cancer	0.00746	0.00891	CcSEcCtD
Frovatriptan—Hiccups—Capecitabine—esophageal cancer	0.00728	0.0087	CcSEcCtD
Frovatriptan—Dehydration—Cisplatin—esophageal cancer	0.00667	0.00796	CcSEcCtD
Frovatriptan—Urine output increased—Capecitabine—esophageal cancer	0.00658	0.00786	CcSEcCtD
Frovatriptan—Abnormal vision—Capecitabine—esophageal cancer	0.00635	0.00758	CcSEcCtD
Frovatriptan—Mental disability—Capecitabine—esophageal cancer	0.00632	0.00755	CcSEcCtD
Frovatriptan—Speech disorder—Methotrexate—esophageal cancer	0.0063	0.00753	CcSEcCtD
Frovatriptan—Ear pain—Capecitabine—esophageal cancer	0.00619	0.0074	CcSEcCtD
Frovatriptan—Sweating increased—Cisplatin—esophageal cancer	0.00603	0.00721	CcSEcCtD
Frovatriptan—Polyuria—Capecitabine—esophageal cancer	0.00602	0.00719	CcSEcCtD
Frovatriptan—Vascular purpura—Capecitabine—esophageal cancer	0.00591	0.00706	CcSEcCtD
Frovatriptan—Eye pain—Capecitabine—esophageal cancer	0.00585	0.00699	CcSEcCtD
Frovatriptan—Hot flush—Capecitabine—esophageal cancer	0.00565	0.00675	CcSEcCtD
Frovatriptan—Amnesia—Capecitabine—esophageal cancer	0.00562	0.00672	CcSEcCtD
Frovatriptan—Menopausal symptoms—Capecitabine—esophageal cancer	0.0056	0.00669	CcSEcCtD
Frovatriptan—Thirst—Capecitabine—esophageal cancer	0.00555	0.00663	CcSEcCtD
Frovatriptan—Dermatitis bullous—Capecitabine—esophageal cancer	0.00553	0.0066	CcSEcCtD
Frovatriptan—Purpura—Capecitabine—esophageal cancer	0.00548	0.00655	CcSEcCtD
Frovatriptan—Acute coronary syndrome—Cisplatin—esophageal cancer	0.00544	0.0065	CcSEcCtD
Frovatriptan—Myocardial infarction—Cisplatin—esophageal cancer	0.00541	0.00647	CcSEcCtD
Frovatriptan—Stomatitis—Cisplatin—esophageal cancer	0.00538	0.00643	CcSEcCtD
Frovatriptan—Conjunctivitis—Cisplatin—esophageal cancer	0.00537	0.00641	CcSEcCtD
Frovatriptan—Pain in extremity—Capecitabine—esophageal cancer	0.00528	0.00631	CcSEcCtD
Frovatriptan—Osteoarthritis—Capecitabine—esophageal cancer	0.00528	0.00631	CcSEcCtD
Frovatriptan—Migraine—Capecitabine—esophageal cancer	0.0052	0.00621	CcSEcCtD
Frovatriptan—Bradycardia—Cisplatin—esophageal cancer	0.00505	0.00603	CcSEcCtD
Frovatriptan—Mood swings—Capecitabine—esophageal cancer	0.005	0.00598	CcSEcCtD
Frovatriptan—Ataxia—Capecitabine—esophageal cancer	0.00497	0.00594	CcSEcCtD
Frovatriptan—Dehydration—Capecitabine—esophageal cancer	0.00491	0.00587	CcSEcCtD
Frovatriptan—Urine output increased—Methotrexate—esophageal cancer	0.0049	0.00585	CcSEcCtD
Frovatriptan—Urinary tract disorder—Cisplatin—esophageal cancer	0.0049	0.00585	CcSEcCtD
Frovatriptan—Urethral disorder—Cisplatin—esophageal cancer	0.00486	0.00581	CcSEcCtD
Frovatriptan—Visual impairment—Cisplatin—esophageal cancer	0.00478	0.00571	CcSEcCtD
Frovatriptan—Muscular weakness—Capecitabine—esophageal cancer	0.00466	0.00557	CcSEcCtD
Frovatriptan—Tinnitus—Cisplatin—esophageal cancer	0.00462	0.00552	CcSEcCtD
Frovatriptan—Flushing—Cisplatin—esophageal cancer	0.0046	0.0055	CcSEcCtD
Frovatriptan—Dysphagia—Capecitabine—esophageal cancer	0.00457	0.00546	CcSEcCtD
Frovatriptan—Polyuria—Methotrexate—esophageal cancer	0.00448	0.00535	CcSEcCtD
Frovatriptan—Sweating increased—Capecitabine—esophageal cancer	0.00445	0.00531	CcSEcCtD
Frovatriptan—Arrhythmia—Cisplatin—esophageal cancer	0.00443	0.00529	CcSEcCtD
Frovatriptan—Malnutrition—Cisplatin—esophageal cancer	0.00432	0.00516	CcSEcCtD
Frovatriptan—Flatulence—Cisplatin—esophageal cancer	0.00425	0.00508	CcSEcCtD
Frovatriptan—Muscle spasms—Cisplatin—esophageal cancer	0.00415	0.00496	CcSEcCtD
Frovatriptan—Depression—Capecitabine—esophageal cancer	0.00406	0.00485	CcSEcCtD
Frovatriptan—Tremor—Cisplatin—esophageal cancer	0.00404	0.00483	CcSEcCtD
Frovatriptan—Acute coronary syndrome—Capecitabine—esophageal cancer	0.00401	0.0048	CcSEcCtD
Frovatriptan—Ill-defined disorder—Cisplatin—esophageal cancer	0.004	0.00478	CcSEcCtD
Frovatriptan—Myocardial infarction—Capecitabine—esophageal cancer	0.00399	0.00477	CcSEcCtD
Frovatriptan—Stomatitis—Capecitabine—esophageal cancer	0.00397	0.00474	CcSEcCtD
Frovatriptan—Conjunctivitis—Capecitabine—esophageal cancer	0.00396	0.00473	CcSEcCtD
Frovatriptan—Osteoarthritis—Methotrexate—esophageal cancer	0.00393	0.0047	CcSEcCtD
Frovatriptan—Malaise—Cisplatin—esophageal cancer	0.00389	0.00465	CcSEcCtD
Frovatriptan—Epistaxis—Capecitabine—esophageal cancer	0.00384	0.00459	CcSEcCtD
Frovatriptan—Convulsion—Cisplatin—esophageal cancer	0.00374	0.00447	CcSEcCtD
Frovatriptan—Mood swings—Methotrexate—esophageal cancer	0.00373	0.00445	CcSEcCtD
Frovatriptan—Bradycardia—Capecitabine—esophageal cancer	0.00372	0.00445	CcSEcCtD
Frovatriptan—Ataxia—Methotrexate—esophageal cancer	0.0037	0.00442	CcSEcCtD
Frovatriptan—Myalgia—Cisplatin—esophageal cancer	0.00367	0.00439	CcSEcCtD
Frovatriptan—Haemoglobin—Capecitabine—esophageal cancer	0.00367	0.00439	CcSEcCtD
Frovatriptan—Rhinitis—Capecitabine—esophageal cancer	0.00366	0.00438	CcSEcCtD
Frovatriptan—Anxiety—Cisplatin—esophageal cancer	0.00366	0.00437	CcSEcCtD
Frovatriptan—Haemorrhage—Capecitabine—esophageal cancer	0.00365	0.00437	CcSEcCtD
Frovatriptan—Hypoaesthesia—Capecitabine—esophageal cancer	0.00364	0.00434	CcSEcCtD
Frovatriptan—Discomfort—Cisplatin—esophageal cancer	0.00363	0.00434	CcSEcCtD
Frovatriptan—Pharyngitis—Capecitabine—esophageal cancer	0.00363	0.00433	CcSEcCtD
Frovatriptan—Urinary tract disorder—Capecitabine—esophageal cancer	0.00361	0.00431	CcSEcCtD
Frovatriptan—Urethral disorder—Capecitabine—esophageal cancer	0.00358	0.00428	CcSEcCtD
Frovatriptan—Anaphylactic shock—Cisplatin—esophageal cancer	0.00352	0.00421	CcSEcCtD
Frovatriptan—Visual impairment—Capecitabine—esophageal cancer	0.00352	0.00421	CcSEcCtD
Frovatriptan—Tachycardia—Cisplatin—esophageal cancer	0.00344	0.00411	CcSEcCtD
Frovatriptan—Tinnitus—Capecitabine—esophageal cancer	0.00341	0.00407	CcSEcCtD
Frovatriptan—Hyperhidrosis—Cisplatin—esophageal cancer	0.00341	0.00407	CcSEcCtD
Frovatriptan—Flushing—Capecitabine—esophageal cancer	0.00339	0.00405	CcSEcCtD
Frovatriptan—Anorexia—Cisplatin—esophageal cancer	0.00336	0.00401	CcSEcCtD
Frovatriptan—Chills—Capecitabine—esophageal cancer	0.00328	0.00392	CcSEcCtD
Frovatriptan—Arrhythmia—Capecitabine—esophageal cancer	0.00327	0.0039	CcSEcCtD
Frovatriptan—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00321	0.00383	CcSEcCtD
Frovatriptan—Mental disorder—Capecitabine—esophageal cancer	0.0032	0.00383	CcSEcCtD
Frovatriptan—Malnutrition—Capecitabine—esophageal cancer	0.00318	0.0038	CcSEcCtD
Frovatriptan—Paraesthesia—Cisplatin—esophageal cancer	0.00316	0.00378	CcSEcCtD
Frovatriptan—Dyspnoea—Cisplatin—esophageal cancer	0.00314	0.00375	CcSEcCtD
Frovatriptan—Flatulence—Capecitabine—esophageal cancer	0.00314	0.00375	CcSEcCtD
Frovatriptan—Dysgeusia—Capecitabine—esophageal cancer	0.00312	0.00372	CcSEcCtD
Frovatriptan—Back pain—Capecitabine—esophageal cancer	0.00308	0.00368	CcSEcCtD
Frovatriptan—Decreased appetite—Cisplatin—esophageal cancer	0.00306	0.00366	CcSEcCtD
Frovatriptan—Muscle spasms—Capecitabine—esophageal cancer	0.00306	0.00365	CcSEcCtD
Frovatriptan—Depression—Methotrexate—esophageal cancer	0.00302	0.00361	CcSEcCtD
Frovatriptan—Pain—Cisplatin—esophageal cancer	0.00301	0.0036	CcSEcCtD
Frovatriptan—Tremor—Capecitabine—esophageal cancer	0.00298	0.00356	CcSEcCtD
Frovatriptan—Stomatitis—Methotrexate—esophageal cancer	0.00295	0.00353	CcSEcCtD
Frovatriptan—Ill-defined disorder—Capecitabine—esophageal cancer	0.00295	0.00353	CcSEcCtD
Frovatriptan—Conjunctivitis—Methotrexate—esophageal cancer	0.00295	0.00352	CcSEcCtD
Frovatriptan—Feeling abnormal—Cisplatin—esophageal cancer	0.0029	0.00347	CcSEcCtD
Frovatriptan—Malaise—Capecitabine—esophageal cancer	0.00287	0.00343	CcSEcCtD
Frovatriptan—Epistaxis—Methotrexate—esophageal cancer	0.00286	0.00342	CcSEcCtD
Frovatriptan—Vertigo—Capecitabine—esophageal cancer	0.00286	0.00342	CcSEcCtD
Frovatriptan—Syncope—Capecitabine—esophageal cancer	0.00285	0.00341	CcSEcCtD
Frovatriptan—Palpitations—Capecitabine—esophageal cancer	0.00281	0.00336	CcSEcCtD
Frovatriptan—Loss of consciousness—Capecitabine—esophageal cancer	0.0028	0.00334	CcSEcCtD
Frovatriptan—Body temperature increased—Cisplatin—esophageal cancer	0.00278	0.00333	CcSEcCtD
Frovatriptan—Haemoglobin—Methotrexate—esophageal cancer	0.00273	0.00327	CcSEcCtD
Frovatriptan—Haemorrhage—Methotrexate—esophageal cancer	0.00272	0.00325	CcSEcCtD
Frovatriptan—Chest pain—Capecitabine—esophageal cancer	0.00271	0.00324	CcSEcCtD
Frovatriptan—Myalgia—Capecitabine—esophageal cancer	0.00271	0.00324	CcSEcCtD
Frovatriptan—Arthralgia—Capecitabine—esophageal cancer	0.00271	0.00324	CcSEcCtD
Frovatriptan—Pharyngitis—Methotrexate—esophageal cancer	0.0027	0.00323	CcSEcCtD
Frovatriptan—Anxiety—Capecitabine—esophageal cancer	0.0027	0.00322	CcSEcCtD
Frovatriptan—Urinary tract disorder—Methotrexate—esophageal cancer	0.00269	0.00321	CcSEcCtD
Frovatriptan—Discomfort—Capecitabine—esophageal cancer	0.00268	0.0032	CcSEcCtD
Frovatriptan—Urethral disorder—Methotrexate—esophageal cancer	0.00267	0.00319	CcSEcCtD
Frovatriptan—Dry mouth—Capecitabine—esophageal cancer	0.00265	0.00316	CcSEcCtD
Frovatriptan—Visual impairment—Methotrexate—esophageal cancer	0.00262	0.00313	CcSEcCtD
Frovatriptan—Confusional state—Capecitabine—esophageal cancer	0.00262	0.00313	CcSEcCtD
Frovatriptan—Hypersensitivity—Cisplatin—esophageal cancer	0.0026	0.0031	CcSEcCtD
Frovatriptan—Shock—Capecitabine—esophageal cancer	0.00255	0.00305	CcSEcCtD
Frovatriptan—Tinnitus—Methotrexate—esophageal cancer	0.00254	0.00303	CcSEcCtD
Frovatriptan—Tachycardia—Capecitabine—esophageal cancer	0.00253	0.00303	CcSEcCtD
Frovatriptan—Asthenia—Cisplatin—esophageal cancer	0.00253	0.00302	CcSEcCtD
Frovatriptan—Hyperhidrosis—Capecitabine—esophageal cancer	0.00251	0.003	CcSEcCtD
Frovatriptan—Anorexia—Capecitabine—esophageal cancer	0.00248	0.00296	CcSEcCtD
Frovatriptan—Chills—Methotrexate—esophageal cancer	0.00244	0.00292	CcSEcCtD
Frovatriptan—Diarrhoea—Cisplatin—esophageal cancer	0.00241	0.00288	CcSEcCtD
Frovatriptan—Mental disorder—Methotrexate—esophageal cancer	0.00238	0.00285	CcSEcCtD
Frovatriptan—Malnutrition—Methotrexate—esophageal cancer	0.00237	0.00283	CcSEcCtD
Frovatriptan—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00237	0.00283	CcSEcCtD
Frovatriptan—Insomnia—Capecitabine—esophageal cancer	0.00235	0.00281	CcSEcCtD
Frovatriptan—Paraesthesia—Capecitabine—esophageal cancer	0.00233	0.00279	CcSEcCtD
Frovatriptan—Dysgeusia—Methotrexate—esophageal cancer	0.00232	0.00277	CcSEcCtD
Frovatriptan—Dyspnoea—Capecitabine—esophageal cancer	0.00232	0.00277	CcSEcCtD
Frovatriptan—Back pain—Methotrexate—esophageal cancer	0.00229	0.00274	CcSEcCtD
Frovatriptan—Dyspepsia—Capecitabine—esophageal cancer	0.00229	0.00273	CcSEcCtD
Frovatriptan—Decreased appetite—Capecitabine—esophageal cancer	0.00226	0.0027	CcSEcCtD
Frovatriptan—Vomiting—Cisplatin—esophageal cancer	0.00224	0.00268	CcSEcCtD
Frovatriptan—Fatigue—Capecitabine—esophageal cancer	0.00224	0.00267	CcSEcCtD
Frovatriptan—Pain—Capecitabine—esophageal cancer	0.00222	0.00265	CcSEcCtD
Frovatriptan—Constipation—Capecitabine—esophageal cancer	0.00222	0.00265	CcSEcCtD
Frovatriptan—Ill-defined disorder—Methotrexate—esophageal cancer	0.0022	0.00263	CcSEcCtD
Frovatriptan—Feeling abnormal—Capecitabine—esophageal cancer	0.00214	0.00256	CcSEcCtD
Frovatriptan—Malaise—Methotrexate—esophageal cancer	0.00214	0.00255	CcSEcCtD
Frovatriptan—Vertigo—Methotrexate—esophageal cancer	0.00213	0.00254	CcSEcCtD
Frovatriptan—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00212	0.00254	CcSEcCtD
Frovatriptan—Nausea—Cisplatin—esophageal cancer	0.00209	0.0025	CcSEcCtD
Frovatriptan—Body temperature increased—Capecitabine—esophageal cancer	0.00205	0.00245	CcSEcCtD
Frovatriptan—Abdominal pain—Capecitabine—esophageal cancer	0.00205	0.00245	CcSEcCtD
Frovatriptan—Convulsion—Methotrexate—esophageal cancer	0.00205	0.00245	CcSEcCtD
Frovatriptan—Chest pain—Methotrexate—esophageal cancer	0.00202	0.00241	CcSEcCtD
Frovatriptan—Myalgia—Methotrexate—esophageal cancer	0.00202	0.00241	CcSEcCtD
Frovatriptan—Arthralgia—Methotrexate—esophageal cancer	0.00202	0.00241	CcSEcCtD
Frovatriptan—Discomfort—Methotrexate—esophageal cancer	0.00199	0.00238	CcSEcCtD
Frovatriptan—Confusional state—Methotrexate—esophageal cancer	0.00195	0.00233	CcSEcCtD
Frovatriptan—Anaphylactic shock—Methotrexate—esophageal cancer	0.00193	0.00231	CcSEcCtD
Frovatriptan—Hypersensitivity—Capecitabine—esophageal cancer	0.00191	0.00229	CcSEcCtD
Frovatriptan—Hyperhidrosis—Methotrexate—esophageal cancer	0.00187	0.00223	CcSEcCtD
Frovatriptan—Asthenia—Capecitabine—esophageal cancer	0.00186	0.00223	CcSEcCtD
Frovatriptan—Anorexia—Methotrexate—esophageal cancer	0.00184	0.0022	CcSEcCtD
Frovatriptan—Pruritus—Capecitabine—esophageal cancer	0.00184	0.00219	CcSEcCtD
Frovatriptan—Diarrhoea—Capecitabine—esophageal cancer	0.00178	0.00212	CcSEcCtD
Frovatriptan—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00176	0.0021	CcSEcCtD
Frovatriptan—Insomnia—Methotrexate—esophageal cancer	0.00175	0.00209	CcSEcCtD
Frovatriptan—Paraesthesia—Methotrexate—esophageal cancer	0.00174	0.00207	CcSEcCtD
Frovatriptan—Dyspnoea—Methotrexate—esophageal cancer	0.00172	0.00206	CcSEcCtD
Frovatriptan—Somnolence—Methotrexate—esophageal cancer	0.00172	0.00205	CcSEcCtD
Frovatriptan—Dizziness—Capecitabine—esophageal cancer	0.00172	0.00205	CcSEcCtD
Frovatriptan—Dyspepsia—Methotrexate—esophageal cancer	0.0017	0.00203	CcSEcCtD
Frovatriptan—Decreased appetite—Methotrexate—esophageal cancer	0.00168	0.00201	CcSEcCtD
Frovatriptan—Fatigue—Methotrexate—esophageal cancer	0.00167	0.00199	CcSEcCtD
Frovatriptan—Pain—Methotrexate—esophageal cancer	0.00165	0.00197	CcSEcCtD
Frovatriptan—Vomiting—Capecitabine—esophageal cancer	0.00165	0.00197	CcSEcCtD
Frovatriptan—Headache—Capecitabine—esophageal cancer	0.00163	0.00194	CcSEcCtD
Frovatriptan—Feeling abnormal—Methotrexate—esophageal cancer	0.00159	0.0019	CcSEcCtD
Frovatriptan—Gastrointestinal pain—Methotrexate—esophageal cancer	0.00158	0.00189	CcSEcCtD
Frovatriptan—Nausea—Capecitabine—esophageal cancer	0.00154	0.00184	CcSEcCtD
Frovatriptan—Body temperature increased—Methotrexate—esophageal cancer	0.00153	0.00183	CcSEcCtD
Frovatriptan—Abdominal pain—Methotrexate—esophageal cancer	0.00153	0.00183	CcSEcCtD
Frovatriptan—Hypersensitivity—Methotrexate—esophageal cancer	0.00142	0.0017	CcSEcCtD
Frovatriptan—Asthenia—Methotrexate—esophageal cancer	0.00139	0.00166	CcSEcCtD
Frovatriptan—Pruritus—Methotrexate—esophageal cancer	0.00137	0.00163	CcSEcCtD
Frovatriptan—Diarrhoea—Methotrexate—esophageal cancer	0.00132	0.00158	CcSEcCtD
Frovatriptan—Dizziness—Methotrexate—esophageal cancer	0.00128	0.00153	CcSEcCtD
Frovatriptan—Vomiting—Methotrexate—esophageal cancer	0.00123	0.00147	CcSEcCtD
Frovatriptan—Headache—Methotrexate—esophageal cancer	0.00121	0.00145	CcSEcCtD
Frovatriptan—Nausea—Methotrexate—esophageal cancer	0.00115	0.00137	CcSEcCtD
Frovatriptan—HTR1D—Signaling Pathways—GDI2—esophageal cancer	0.000546	0.00335	CbGpPWpGaD
Frovatriptan—CYP1A2—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000544	0.00334	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—GDI2—esophageal cancer	0.000535	0.00328	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR ligand binding—ANXA1—esophageal cancer	0.000533	0.00327	CbGpPWpGaD
Frovatriptan—HTR1A—SIDS Susceptibility Pathways—HIF1A—esophageal cancer	0.000532	0.00327	CbGpPWpGaD
Frovatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—ANXA1—esophageal cancer	0.000522	0.0032	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR ligand binding—ANXA1—esophageal cancer	0.000522	0.0032	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR ligand binding—SST—esophageal cancer	0.000518	0.00318	CbGpPWpGaD
Frovatriptan—CYP1A2—Biological oxidations—GSTO1—esophageal cancer	0.000513	0.00315	CbGpPWpGaD
Frovatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	0.000508	0.00312	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR ligand binding—SST—esophageal cancer	0.000508	0.00311	CbGpPWpGaD
Frovatriptan—CYP1A2—Metapathway biotransformation—GSTO1—esophageal cancer	0.000506	0.00311	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR ligand binding—GHRL—esophageal cancer	0.000505	0.0031	CbGpPWpGaD
Frovatriptan—CYP1A2—Aryl Hydrocarbon Receptor—RB1—esophageal cancer	0.000499	0.00306	CbGpPWpGaD
Frovatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	0.000495	0.00304	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR ligand binding—GHRL—esophageal cancer	0.000495	0.00304	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.000489	0.003	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR ligand binding—GNG7—esophageal cancer	0.000485	0.00298	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—ADCYAP1—esophageal cancer	0.000444	0.00273	CbGpPWpGaD
Frovatriptan—HTR1A—SIDS Susceptibility Pathways—CREBBP—esophageal cancer	0.000435	0.00267	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR ligand binding—CXCL2—esophageal cancer	0.000428	0.00262	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—AKAP13—esophageal cancer	0.000423	0.00259	CbGpPWpGaD
Frovatriptan—CYP1A2—Biological oxidations—ALDH2—esophageal cancer	0.000418	0.00257	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—AKAP13—esophageal cancer	0.000414	0.00254	CbGpPWpGaD
Frovatriptan—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—esophageal cancer	0.00041	0.00252	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—GDI2—esophageal cancer	0.000407	0.0025	CbGpPWpGaD
Frovatriptan—CYP1A2—Biological oxidations—GSTT1—esophageal cancer	0.000398	0.00244	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR ligand binding—ANXA1—esophageal cancer	0.000397	0.00244	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—KMT2D—esophageal cancer	0.000395	0.00242	CbGpPWpGaD
Frovatriptan—CYP1A2—Biological oxidations—CYP2A6—esophageal cancer	0.000393	0.00241	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR ligand binding—SST—esophageal cancer	0.000387	0.00237	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—PDE4D—esophageal cancer	0.000387	0.00237	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—KMT2D—esophageal cancer	0.000387	0.00237	CbGpPWpGaD
Frovatriptan—CYP1A2—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000384	0.00236	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—AKAP13—esophageal cancer	0.000384	0.00235	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—PDE4D—esophageal cancer	0.000379	0.00232	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR ligand binding—GHRL—esophageal cancer	0.000377	0.00231	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—AKAP13—esophageal cancer	0.000376	0.00231	CbGpPWpGaD
Frovatriptan—CYP1A2—Biological oxidations—PTGS1—esophageal cancer	0.000373	0.00229	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—GNG7—esophageal cancer	0.000368	0.00226	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—GNG7—esophageal cancer	0.00036	0.00221	CbGpPWpGaD
Frovatriptan—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—esophageal cancer	0.000359	0.0022	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—ADCYAP1—esophageal cancer	0.000352	0.00216	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—PDE4D—esophageal cancer	0.000351	0.00215	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—ADCYAP1—esophageal cancer	0.000345	0.00211	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—PDE4D—esophageal cancer	0.000344	0.00211	CbGpPWpGaD
Frovatriptan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—esophageal cancer	0.000341	0.00209	CbGpPWpGaD
Frovatriptan—CYP1A2—Aryl Hydrocarbon Receptor—EP300—esophageal cancer	0.000341	0.00209	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—GNG7—esophageal cancer	0.000334	0.00205	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—GNG7—esophageal cancer	0.000327	0.00201	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—CXCL2—esophageal cancer	0.000324	0.00199	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—WWOX—esophageal cancer	0.000322	0.00197	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—CXCL2—esophageal cancer	0.000317	0.00195	CbGpPWpGaD
Frovatriptan—CYP1A2—Biological oxidations—CYP1B1—esophageal cancer	0.000317	0.00195	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—AKAP13—esophageal cancer	0.000315	0.00193	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—WWOX—esophageal cancer	0.000315	0.00193	CbGpPWpGaD
Frovatriptan—CYP1A2—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000313	0.00192	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—FKBP1A—esophageal cancer	0.000306	0.00188	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000306	0.00188	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—ANXA1—esophageal cancer	0.000301	0.00185	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—FKBP1A—esophageal cancer	0.0003	0.00184	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—WIF1—esophageal cancer	0.000299	0.00184	CbGpPWpGaD
Frovatriptan—CYP1A2—Biological oxidations—CYP19A1—esophageal cancer	0.000298	0.00183	CbGpPWpGaD
Frovatriptan—CYP1A2—Aryl Hydrocarbon Receptor—MYC—esophageal cancer	0.000297	0.00182	CbGpPWpGaD
Frovatriptan—HTR1A—SIDS Susceptibility Pathways—EP300—esophageal cancer	0.000296	0.00182	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—ANXA1—esophageal cancer	0.000295	0.00181	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—KMT2D—esophageal cancer	0.000294	0.00181	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—CXCL2—esophageal cancer	0.000294	0.0018	CbGpPWpGaD
Frovatriptan—CYP1A2—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000294	0.0018	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—SST—esophageal cancer	0.000293	0.0018	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—WIF1—esophageal cancer	0.000293	0.0018	CbGpPWpGaD
Frovatriptan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—esophageal cancer	0.000291	0.00178	CbGpPWpGaD
Frovatriptan—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—esophageal cancer	0.000291	0.00178	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—PDE4D—esophageal cancer	0.000288	0.00177	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—CXCL2—esophageal cancer	0.000288	0.00177	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—SST—esophageal cancer	0.000287	0.00176	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—AKAP13—esophageal cancer	0.000286	0.00176	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—GHRL—esophageal cancer	0.000285	0.00175	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—GHRL—esophageal cancer	0.00028	0.00172	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—CSNK1A1—esophageal cancer	0.000276	0.00169	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—GNG7—esophageal cancer	0.000274	0.00168	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—ANXA1—esophageal cancer	0.000273	0.00168	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—CSNK1A1—esophageal cancer	0.00027	0.00166	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—ANXA1—esophageal cancer	0.000268	0.00164	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—SST—esophageal cancer	0.000266	0.00163	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—ADCYAP1—esophageal cancer	0.000262	0.00161	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—PDE4D—esophageal cancer	0.000262	0.00161	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—SST—esophageal cancer	0.00026	0.0016	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—GHRL—esophageal cancer	0.000259	0.00159	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—PFN1—esophageal cancer	0.000258	0.00158	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—GHRL—esophageal cancer	0.000254	0.00156	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—PFN1—esophageal cancer	0.000253	0.00155	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—GNG7—esophageal cancer	0.000249	0.00153	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—CXCL2—esophageal cancer	0.000242	0.00148	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—WWOX—esophageal cancer	0.00024	0.00147	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—ELMO1—esophageal cancer	0.000232	0.00142	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—FKBP1A—esophageal cancer	0.000228	0.0014	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—ELMO1—esophageal cancer	0.000227	0.00139	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—AKAP13—esophageal cancer	0.000227	0.00139	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—ANXA1—esophageal cancer	0.000225	0.00138	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—WIF1—esophageal cancer	0.000223	0.00137	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—AKAP13—esophageal cancer	0.000222	0.00136	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—CXCL2—esophageal cancer	0.000219	0.00135	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—SST—esophageal cancer	0.000219	0.00134	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—GHRL—esophageal cancer	0.000213	0.00131	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000209	0.00128	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—PDE4D—esophageal cancer	0.000207	0.00127	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000207	0.00127	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CSNK1A1—esophageal cancer	0.000206	0.00126	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000205	0.00126	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—ANXA1—esophageal cancer	0.000204	0.00125	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—PDE4D—esophageal cancer	0.000203	0.00125	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—SST—esophageal cancer	0.000198	0.00122	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—GNG7—esophageal cancer	0.000197	0.00121	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—GHRL—esophageal cancer	0.000193	0.00119	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—GNG7—esophageal cancer	0.000193	0.00118	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—PFN1—esophageal cancer	0.000193	0.00118	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—XIAP—esophageal cancer	0.000185	0.00113	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—XIAP—esophageal cancer	0.000181	0.00111	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.00018	0.00111	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—CTNNA1—esophageal cancer	0.000175	0.00107	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—CXCL2—esophageal cancer	0.000174	0.00107	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—ELMO1—esophageal cancer	0.000173	0.00106	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—CTNNA1—esophageal cancer	0.000171	0.00105	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—CXCL2—esophageal cancer	0.00017	0.00104	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—AKAP13—esophageal cancer	0.000169	0.00104	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—PSME2—esophageal cancer	0.000162	0.000996	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—PSME1—esophageal cancer	0.000162	0.000996	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—ANXA1—esophageal cancer	0.000162	0.000991	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—SLC52A3—esophageal cancer	0.00016	0.000983	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—BLVRB—esophageal cancer	0.00016	0.000983	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—PSME1—esophageal cancer	0.000159	0.000975	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—PSME2—esophageal cancer	0.000159	0.000975	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—ANXA1—esophageal cancer	0.000158	0.000971	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—SST—esophageal cancer	0.000157	0.000964	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000156	0.000958	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—PDE4D—esophageal cancer	0.000155	0.000949	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—SST—esophageal cancer	0.000154	0.000944	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—GHRL—esophageal cancer	0.000153	0.00094	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—NOTCH3—esophageal cancer	0.000153	0.00094	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—FBXW7—esophageal cancer	0.000151	0.000924	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—NOTCH3—esophageal cancer	0.00015	0.00092	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—GHRL—esophageal cancer	0.00015	0.00092	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—FBXW7—esophageal cancer	0.000148	0.000905	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—GNG7—esophageal cancer	0.000147	0.000903	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000143	0.000878	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—XIAP—esophageal cancer	0.000138	0.000846	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—NOTCH2—esophageal cancer	0.000137	0.000843	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—SLC10A2—esophageal cancer	0.000136	0.000836	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—CA1—esophageal cancer	0.000136	0.000836	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—NOTCH2—esophageal cancer	0.000135	0.000825	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CTNNA1—esophageal cancer	0.00013	0.0008	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CXCL2—esophageal cancer	0.00013	0.000795	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—CA2—esophageal cancer	0.000125	0.000764	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—TGFBR2—esophageal cancer	0.000122	0.000748	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000122	0.000747	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—PSME1—esophageal cancer	0.000121	0.000743	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—PSME2—esophageal cancer	0.000121	0.000743	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—ANXA1—esophageal cancer	0.000121	0.000739	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—TGFBR2—esophageal cancer	0.000119	0.000732	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—SST—esophageal cancer	0.000117	0.000719	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—ADH7—esophageal cancer	0.000116	0.00071	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—PLCE1—esophageal cancer	0.000116	0.00071	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—SMAD4—esophageal cancer	0.000115	0.000708	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000114	0.000702	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—NOTCH3—esophageal cancer	0.000114	0.000701	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—GHRL—esophageal cancer	0.000114	0.000701	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—SMAD4—esophageal cancer	0.000113	0.000693	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—FBXW7—esophageal cancer	0.000112	0.00069	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—NOTCH2—esophageal cancer	0.000102	0.000629	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—ADH1B—esophageal cancer	0.000102	0.000623	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—TYMP—esophageal cancer	9.7e-05	0.000595	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—CYP26A1—esophageal cancer	9.44e-05	0.000579	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—HIF1A—esophageal cancer	9.44e-05	0.000579	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—HIF1A—esophageal cancer	9.24e-05	0.000567	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—ALOX15—esophageal cancer	9.2e-05	0.000564	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—TGFBR2—esophageal cancer	9.09e-05	0.000558	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—KDR—esophageal cancer	9.03e-05	0.000554	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—KDR—esophageal cancer	8.84e-05	0.000542	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—GSTO1—esophageal cancer	8.78e-05	0.000538	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—TPI1—esophageal cancer	8.78e-05	0.000538	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—SMAD4—esophageal cancer	8.6e-05	0.000528	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—NOTCH1—esophageal cancer	8.5e-05	0.000522	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—ALDOB—esophageal cancer	8.41e-05	0.000516	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—NOTCH1—esophageal cancer	8.33e-05	0.000511	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—GAPDH—esophageal cancer	8.1e-05	0.000497	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—CRABP1—esophageal cancer	8.03e-05	0.000492	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—CREBBP—esophageal cancer	7.71e-05	0.000473	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—GNG7—esophageal cancer	7.63e-05	0.000468	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—EGFR—esophageal cancer	7.58e-05	0.000465	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—CREBBP—esophageal cancer	7.55e-05	0.000463	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—EGFR—esophageal cancer	7.42e-05	0.000455	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—PIK3CA—esophageal cancer	7.24e-05	0.000444	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—ALDH2—esophageal cancer	7.15e-05	0.000439	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—PIK3CA—esophageal cancer	7.09e-05	0.000435	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—HIF1A—esophageal cancer	7.04e-05	0.000432	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—NOS3—esophageal cancer	6.9e-05	0.000424	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—GSTT1—esophageal cancer	6.8e-05	0.000417	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—NOS3—esophageal cancer	6.76e-05	0.000415	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—KDR—esophageal cancer	6.73e-05	0.000413	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—CYP2A6—esophageal cancer	6.73e-05	0.000413	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	6.7e-05	0.000411	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—PIK3CA—esophageal cancer	6.57e-05	0.000403	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—ERBB2—esophageal cancer	6.46e-05	0.000396	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—PIK3CA—esophageal cancer	6.44e-05	0.000395	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—ENO1—esophageal cancer	6.38e-05	0.000391	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—PTGS1—esophageal cancer	6.38e-05	0.000391	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—NOTCH1—esophageal cancer	6.34e-05	0.000389	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—ERBB2—esophageal cancer	6.32e-05	0.000388	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—PSME1—esophageal cancer	6.28e-05	0.000385	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—PSME2—esophageal cancer	6.28e-05	0.000385	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CREBBP—esophageal cancer	5.75e-05	0.000353	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—CCND1—esophageal cancer	5.7e-05	0.00035	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—EGFR—esophageal cancer	5.65e-05	0.000347	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—CCND1—esophageal cancer	5.59e-05	0.000343	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—CDKN1A—esophageal cancer	5.52e-05	0.000339	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	5.49e-05	0.000337	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—CYP1B1—esophageal cancer	5.42e-05	0.000333	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—CDKN1A—esophageal cancer	5.4e-05	0.000332	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—PIK3CA—esophageal cancer	5.4e-05	0.000331	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—EP300—esophageal cancer	5.25e-05	0.000322	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—NOS3—esophageal cancer	5.15e-05	0.000316	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—EP300—esophageal cancer	5.14e-05	0.000315	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—CYP19A1—esophageal cancer	5.1e-05	0.000313	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—PIK3CA—esophageal cancer	4.9e-05	0.000301	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—ERBB2—esophageal cancer	4.82e-05	0.000295	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—HMOX1—esophageal cancer	4.65e-05	0.000285	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—MYC—esophageal cancer	4.58e-05	0.000281	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	4.56e-05	0.00028	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—MYC—esophageal cancer	4.48e-05	0.000275	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—EGFR—esophageal cancer	4.48e-05	0.000275	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—ABCB1—esophageal cancer	4.46e-05	0.000274	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—EGFR—esophageal cancer	4.38e-05	0.000269	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CCND1—esophageal cancer	4.25e-05	0.000261	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CDKN1A—esophageal cancer	4.12e-05	0.000253	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—EP300—esophageal cancer	3.92e-05	0.00024	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—PIK3CA—esophageal cancer	3.88e-05	0.000238	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—PIK3CA—esophageal cancer	3.8e-05	0.000233	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—TP53—esophageal cancer	3.76e-05	0.000231	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—TP53—esophageal cancer	3.68e-05	0.000226	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—MYC—esophageal cancer	3.41e-05	0.000209	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	3.38e-05	0.000207	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—EGFR—esophageal cancer	3.34e-05	0.000205	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—CREBBP—esophageal cancer	2.98e-05	0.000183	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—PIK3CA—esophageal cancer	2.9e-05	0.000178	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—TP53—esophageal cancer	2.8e-05	0.000172	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—NOS3—esophageal cancer	2.67e-05	0.000164	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—PTGS2—esophageal cancer	2.44e-05	0.00015	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—EP300—esophageal cancer	2.03e-05	0.000125	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—PIK3CA—esophageal cancer	1.5e-05	9.22e-05	CbGpPWpGaD
